# A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

> **NCT05153499** · PHASE3 · TERMINATED · sponsor: **Finch Research and Development LLC.** · enrollment: 19 (actual)

## Conditions studied

- Recurrent C. Difficile Infection

## Interventions

- **BIOLOGICAL:** CP101
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05153499
- **Lead sponsor:** Finch Research and Development LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-15
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The termination of FIN-CDI-301 (PRISM4) is based on the voluntary, business-related decision of the sponsor.
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153499, "A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05153499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*